Company profile
OMEROS CORP
NASDAQ:OMERBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NARSOPLIMAB | phase3 | — | 4 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (24)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02132312 | phase3 | completed | 2014-07-01 | 2016-09-12 | Omeros Corporation | A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement |
| NCT00624845 | phase2_3 | completed | 2007-12-01 | 2009-05-01 | Omeros Corporation | Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy |
| NCT05855083 | phase2 | recruiting | 2023-05-01 | 2025-12-01 | Omeros Corporation | Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA |
| NCT00226759 | phase3 | completed | 2004-11-01 | 2010-09-01 | Omeros Corporation | Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction |
| NCT00226772 | phase3 | completed | 2005-06-01 | 2010-09-01 | Omeros Corporation | Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761152 | BLA | Omeros Corporation | ||||
Loading… | ||||||